VOR Vor Biopharma Inc.

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, Vor designs these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells. Vorís platform could be used to potentially change the treatment paradigm of both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell treatments.

$3.93
As of 10/03/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/04/2021
Outstanding shares:  38,056,306
Average volume:  126,850
Market cap:   $148,419,593
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BLCD876
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.76
PS ratio:   0.00
Return on equity:   -40.07%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy